Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is advancing gene therapy solutions for ocular and rare diseases, with a focus on chronic retinal conditions.The consensus price target for Adverum's stock is $4.83, with Chardan Capital setting a lower target of$2, indicating differing analyst opinions.Adverum's pivotal Phase 3 ARTEMIS trial for wet AMD treatment is progressing ahead of schedule, with topline data expected in Q1 2027, and a $10 million private placement from Frazier Life Sciences supports ongoin ...